JRCT ID: jRCTs051180239
Registered date:30/03/2019
AMED Preclinical study
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | mild cognitive impairment, preclinical Alzheimer disease |
| Date of first enrollment | 11/01/2017 |
| Target sample size | 500 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | Examination by unapproved PET diagnostic drug |
Outcome(s)
| Primary Outcome | Amyloid PET |
|---|---|
| Secondary Outcome | Abeta protein in CSF |
Key inclusion & exclusion criteria
| Age minimum | >= 60age old |
|---|---|
| Age maximum | < 85age old |
| Gender | Both |
| Include criteria | Subjects at the preclinical AD stage |
| Exclude criteria | Patients with dementia |
Related Information
| Primary Sponsor | Shimada Hiroyuki |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | AMED |
| Secondary ID(s) | UMIN000019926 |
Contact
| Public contact | |
| Name | Hiroyuki Shimada |
| Address | 1-4-3, Asahi-machi Abeno-ku, Osaka, Japan Osaka Japan 5458585 |
| Telephone | +81-666466185 |
| h.shimada@med.osaka-cu.ac.jp | |
| Affiliation | Osaka City University Graduate School of Medicine. |
| Scientific contact | |
| Name | Hiroyuki Shimada |
| Address | 1-4-3, Asahi-machi Abeno-ku, Osaka, Japan Osaka Japan 545-8585 |
| Telephone | +81-6-6646-6185 |
| h.shimada@med.osaka-cu.ac.jp | |
| Affiliation | Osaka City University Hospital |